Teva, Pfizer and EQT among final three bidders for Ratiopharm
The German business daily Handelsblatt reports that acquisitive Israeli generics giant Teva Pharmaceutical Industries, global drugs behemoth Pfizer and the Swedish private equity fund EQT are the three finalists for privately-owned German generics drug company Ratiopharm GmbH, which was put up for sale after the suicide of its principal, Adolf Merckle, in January last year.
The German billionaire entrepreneur, who also owned the country's largest drug wholesaler Phoenix Pharmahandel, had amassed substantial debts, reported to have been around $6.8 billion, ahead of his action.
The finalists will make their bids in early February. French drug major Sanofi Aventis, which has been increasing its footprint on the generics landscape, and China's Sinopharm Group withdrew from the tender in December.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze